CARCINOMA HEPATOCELULAR – UMA REVISÃO BIBLIOGRÁFICA
Resumo
Introdução: globalmente, são diagnosticados mais de meio milhão de casos de carcinoma hepatocelular (CHC) ao ano. É o terceiro câncer em mortalidade e o sexto em incidência. Os fatores de risco são bastante conhecidos e descritos na literatura - a cirrose, o principal deles, é encontrada em 90% dos casos. Em termos globais, a etiologia mais comum é o vírus da hepatite B (HBV), seguido do vírus da hepatite C (HCV). Material e métodos: realizada uma busca na base de dados do Medline a partir da ferramente MeSH do site Pubmed no dia 11 de março de 2014. Foram usadas como palavras-chave: “carcinoma hepatocellular/epidemiology”. Restringindo a revisões sistemáticas ou revisões publicadas nos últimos 5 anos, foram encontrados 154 artigos. A partir da leitura do título e abstract, o número foi reduzido a 52. Adicionalmente, incluímos artigos referenciados nos trabalhos selecionados. Resultados e Discussão: a distribuição do CHC no mundo é bastante heterogênea e dinâmica. Oitenta e dois por cento dos novos casos concentram-se em países em desenvolvimento, com a China contemplando sozinha 55%. Localidades de alta incidência de CHC normalmente são endêmicas para o HBV. Já em regiões de baixa incidência para o câncer, a etiologia predominante é o HCV. Somados, os vírus são encontrados em 80% de todos os casos. Outra característica é o maior comprometimento de homens – no Brasil, 78%. Os fatores de risco, além dos vírus, são o etilismo, hemocromatose, aflatoxina B1, hepatite autoimune, obesidade, Diabetes, Doença Hepática Gordurosa Não-Alcoólica (NALFD), Esteatohepatite Não-Alcoólica (NASH) e tabagismo.
Palavras-chave
Texto completo:
PDFReferências
Torre L a, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin; 65: 87–108
Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. In: Gastroenterology. 2004.
Kim BK, Han K-H, Ahn SH. Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology; 81: 41–49.
Kew MC, Hodkinson J, Paterson AC, et al. Hepatitis-B virus infection in black children with hepatocellular carcinoma. J Med Virol; 9: 201–207, 1982.
Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–538.
Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303–1310.
Blonski W. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol; 16: 3603, 2010.
Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481–488.
Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–1130.
Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001; 34: 748–755.
Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. In: Oncology. 2002, pp. 8–17.
Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: Worldwide incidence and trends. In: Gastroenterology. 2004.
Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137–145.
Cancer incidence in five continents. Volume VII. IARC Sci Publ 1997; i–xxxiv, 1–1240.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology; 142: 1264–1273.e1, 2012.
Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 1988; 8: 1679–1683.
Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology; 48: 863–870, 2008.
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–750.
Carrilho FJ, Kikuchi L, Branco F, et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clin Sao Paulo Brazil; 65: 1285–1290, 2010.
Ministério da Saúde. Câncer no Brasil - Dados dos Registros de Base Populacional, 2005.
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030–3044.
Kim SR, Kudo M, Hino O, et al. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008; 75 Suppl 1: 13–16.
Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007; 96: 1127–1134.
Summers J. Three recently described animal virus models for human hepatitis B virus. Hepatology; 1: 179–183, 1981.
Yang JD, Kim WR, Coelho R, et al. Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2011; 9: 64–70.
Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347–354.
Shi J, Zhu L, Liu S, et al. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92: 607–612.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–352.
Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA; 295: 65–73, 2006.
Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–1531.
SUNG JJY, TSOI KKF, WONG VWS, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther; 28: 1067–1077, 2008.
Salgia R, Singal AG. Hepatocellular carcinoma and other liver lesions. Med Clin North Am; 98: 103–18, 2014.
Ni Y, Chang M, Huang L, et al. Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination. Ann Intern Med 2001; 135: 796–800.
Fasani P, Sangiovanni A, De Fazio C, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29: 1704–1707.
Stroffolini T, Andreone P, Andriulli A, et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 1999; 56: 189–192
Gower E, Estes C C, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol; 61: S45–S57, 2014.
Morgan RL, Baack B, Smith BD, et al. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma. Ann Intern Med 2013; 158: 329–337.
Seeff LB. The history of the ‘natural history’ of hepatitis C (1968-2009). Liver Int 2009; 29 Suppl 1: 89–99.
Thomas DL, Seeff LB. Natural history of hepatitis C. Clinics in Liver Disease 2005; 9: 383–398.
Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323–331.
Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology; 49: 1954–61, 2009.
Christensen E. Portal hypertension and development of hepatocellular carcinoma: Factors influencing significance in prognostic models. J Hepatol; 50: 848–849, 2009.
Raimondi S, Bruno S, Mondelli MU, et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis. J Hepatol; 50: 1142–1154, 2009.
Ribes J, Clèries R, Esteban L, et al. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 2008; 49: 233–242.
Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 661–662.
Poordad F, McCone J, Bacon BR, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med; 364: 1195–1206, 2011.
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. N Engl J Med; 364: 1207–1217, 2011.
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–2428.
Shen Y-C, Hsu C, Cheng C-C, et al. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology; 82: 275–89, 2012.
Papatheodoridis G V, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689–698.
Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug and Alcohol Dependence 2004; 74: 223–234.
Pincock S. Binge drinking on rise in UK and elsewhere. Lancet; 362: 1126–1127, 2003.
Wang LY, You SL, Lu SN, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: A cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003; 14: 241–250.
El-Serag HB, Mason a C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227–3230.
La Vecchia C. Alcohol and liver cancer. Eur J Cancer Prev; 16: 495–497, 2007.
Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biological chemistry 2006; 387: 349–360.
Corrao G, Bagnardi V, Zambon A, et al. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med (Baltim); 38: 613–619, 2004.
Kuper H, Ye W, Broomé U, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001; 34: 714–718.
Donato F, Gelatti U, Limina RM, et al. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006; 25: 3756–3770.
Kuper H, Ye W, Broomé U, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001; 34: 714–718.
Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Research 1994; 54: 4855–4878.
Seitz HK, Pöschl G, Simanowski UA. Alcohol and cancer. Recent Dev Alcohol 1998; 14: 67–95.
Chiesa R, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000; 9: 213–216.
Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 65–75.
Grando-Lemaire V, Guettier C, Chevret S, et al. Hepatocellular carcinoma without cirrhosis in the West: Epidemiological factors and histopathology of the non-tumorous liver. J Hepatol 1999; 31: 508–513.
Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806–813.
El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. In: Gastroenterology. 2004.
El-Serag HB, Lau M, Eschbach K, et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007; 167: 1983–1989.
El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 2007; 132: 2557–2576.
Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005; 3: 1150–1159.
Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer Risk in Patients with Hereditary Hemochromatosis and in Their First-Degree Relatives. Gastroenterology 2003; 125: 1733–1741.
Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33: 647–651.
Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–1362.
Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol 2000; 32: 48–62.
Kowdley K V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology; 127: S79–S86, 2004.
Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai , People’s Republic of China . A Follow-Up Markers of China. Cancer Epidemiol Biomark 1994; 3: 3–10.
Magnussen A, Parsi MA. Aflatoxins, hepatocellular carcinoma and public health. World Journal of Gastroenterology, 2013, pp. 1508–1512.
López C, Ramos L, Bulacio L, et al. Aflatoxin B1 content in patients with hepatic diseases. Medicina (B Aires) 2002; 62: 313–316.
Strosnider H, Azziz-Baumgartner E, Banziger M, et al. Workgroup report: Public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect 2006; 114: 1898–1903.
Williams JH, Phillips TD, Jolly PE, et al. Human aflatoxicosis in developing countries: A review of toxicology, exposure, potential health consequences, and interventions. American Journal of Clinical Nutrition 2004; 80: 1106–1122.
Liu Y, Chang C, Marsh G, et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer; 48: 2125–2136, 2012.
Chen CJ, Zhang YJ, Lu SN, et al. Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. Hepatology 1992; 16: 1150–1155.
Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005; 51: 313–333.
Czaja AJ. Special clinical challenges in autoimmune hepatitis: The elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Seminars in Liver Disease 2009; 29: 315–330.
Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol 2009; 15: 2314–2328.
Czaja AJ, Marques R, Santos D, et al. No Title. Dig Dis Sci; 43: 2149–2155, 1998.
Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005; 11: 1862–1866.
Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 2051–2057.
Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944–1948.
Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology; 8: 1679–1683, 1988.
Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044–1049.
Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005; 25: 734–739.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420–427.
Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005; 129: 113–121.
Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The dionysos nutrition and liver study. Hepatology 2005; 42: 44–52.
Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69–S73.
Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer, 2007
Davila J a, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut; 54: 533–9, 2005.
Mizoue T, Tokui N, Nishisaka K, et al. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Int J Epidemiol; 29: 232–7, 2000.
Zhu K, Moriarty C, Caplan LS, et al. Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control; 18: 315–21, 2007.
Evans AA, Chen G, Ross EA, et al. Eight-Year Follow-Up of the 90 , 000-Person Haimen City Cohort : I . Hepatocellular Carcinoma Mortality , Risk Factors , and Gender Differences Eight-Year Follow-Up of the 90 , 000-Person Haimen City Cohort : I . Hepatocellular Carcinoma Mortality , Risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 369–376.
Sun C -a. Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan. Am J Epidemiol; 157: 674–682, 2003.
Mori M, Hara M, Wada I, et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000; 151: 131–139.
Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: A meta-analysis. Int J Cancer 2008; 122: 155–164.
Larsson SC, Wolk A. Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis. Gastroenterology; 132: 1740–1745, 2007.
Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998; 27: 438–443.
Gelatti U, Covolo L, Franceschini M, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: A case-control study. Journal of Hepatology 2005; 42: 528–534.
Montella M, Polesel J, La Vecchia C, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007; 120: 1555–1559.
Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008; 48: 129–136.
Inoue M, Yoshimi I, Sobue T, et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst 2005; 97: 293–300.
DOI: http://dx.doi.org/10.5380/rmu.v2i4.44264
DOI (PDF): http://dx.doi.org/10.5380/rmu.v2i4.44264.g27158
Apontamentos
- Não há apontamentos.
